Trial Profile
Phase 2a Open Label Study, Safety and Tolerability of Combination Antiretroviral Therapy (Triumeq) in Participants With Amyotrophic Lateral Sclerosis (ALS) - The Lighthouse Project
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Acronyms Lighthouse
- 15 Apr 2021 Results assessing effect of 24-weeks in 29 ALS patient, published in the Journal of the Neurological Sciences.
- 20 Aug 2019 Status changed from active, no longer recruiting to completed.
- 13 Jul 2017 Planned End Date changed from 1 Jun 2020 to 1 Jun 2018.